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ABSTRACT
Background In recent years, the effectiveness of 
magnetic resonance imaging (MRI)-ultrasound fusion 
targeted biopsy (MRF-TB) has been widely reported. 
In this study, we assessed the effect of reduction of the 
number of systematic biopsy (SB) cores on the cancer 
detection rate (CDR).
Methods Patients with a high prostate-specific 
antigen (PSA) level underwent prostate MRI. The 
Prostate Imaging-Reporting and Data System version 2 
(PI-RADS) was then used to rate the lesions. The inclu-
sion criteria were as follows: (1) PSA level between 4.0 
and 30.0 ng/mL and (2) patients with one or more lesions 
on MRI and a PI-RADS score of 3 or more. All enrolled 
patients were SB naïve or had a history of one or more 
prior negative SBs. A total of 104 Japanese met this selec-
tion criterion. We have traditionally performed 14-core 
SB following the MRF-TB. In this study, the CDRs of 10-
core SB methods, excluding biopsy results at the center of 
the base and mid-level on both sides, were compared with 
those of the conventional biopsy method.
Results We compared CDRs of the 14-core and 10-
core SBs used in combination. The overall CDR was 
55.8% for the former and 55.8% for the latter, thereby 
indicating that there was no significant difference (P = 
1.00) between the two. In addition, the CDRs of csPCa 
were 51.9% for the former and 51.1% for the latter, which 
indicated that there was no significant difference (P = 
0.317).
Conclusion There was no significant difference in the 
CDR when the number of SB cores to be used in combi-
nation was 14 and 10.
Key words Image-guided biopsy; magnetic resonance 
imaging; prostate; prostatic neoplasms; ultrasonography
Prostate biopsy is essential for diagnosis, risk stratifica-
tion, and treatment planning in patients with prostate 
cancer (PCa). Only 13% to 33% of PCa cases manifest 
as a single lesion in the prostate. In most cases, PCa 
lesions occur in multiple forms.1 Therefore, systemic 
biopsy (SB) has emerged as a useful diagnostic and 
prognostic tool. However, SB has several limitations. 
For instance, SB-guided transrectal ultrasound (TRUS) 
may lead to the underdiagnosis of clinically significant 
prostate cancer (csPCa) or may result in the overdi-
agnosis of clinically insignificant PCa (cisPCa). The 
overdiagnosis and overtreatment of PCa have become 
a serious clinical problem. Hence, new methods are 
required to improve the accuracy of prostate biopsy.
In the recent years, the usefulness of multipa-
rametric magnetic resonance imaging (mpMRI) in 
diagnosing csPCa has been reported. In particular, the 
location of cancer noted on an mpMRI image is fused 
with the TRUS image using a software. A fusion image 
is formed, which then guides targeted biopsy (TB). This 
method is known as the MRI-TRUS fusion-targeted 
biopsy (MRF-TB). Several meta-analyses have reported 
that MRF-TB had a higher detection rate of csPCa and 
a lower number of required biopsy samples compared 
with TRUS biopsy.2–5
Many medical institutions use TB and SB in com-
bination, but the exact number of biopsy cores required 
in each procedure remains unknown. The number of 
biopsy cores is determined at the discretion of the exam-
iner based on the size and position of the lesion and the 
Prostate Imaging-Reporting and Data System version 2 
(PI-RADS) score. Our facility performed a 2-core TB 
and a 14-core SB for each MRI lesion. However, there 
were numerous reports that a higher number of cores 
in prostate biopsy not only took more time, but also 
increased the incidence of complications. Reducing the 
number of biopsy cores may reduce patient burden.
In this study, the PI-RADS score was used for 
MRI evaluation of PCa. PI-RADS corresponded to the 
patient’s likelihood of having csPCa. It was based on 
a combination of mpMRI findings on a 5-point scale. 
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Other findings such as prostate-specific antigen (PSA) 
levels, rectal findings, medical history, or treatment 
strategy were not accounted in the PI-RADS score.
We assessed the performance of PI-RADS in PCa 
detection. The PI-RADS score was retrospectively as-
signed. Furthermore, we evaluated whether the cancer 
detection rate (CDR) would be the same even if the 
number of biopsy cores used in the conventional 14-
core SBs at our institution was reduced to 10-core. We 
compared the 14-core and 10-core SBs in terms of their 
PCa detection rates.
MATERIALS AND METHODS
Ethical approval for the collection and analysis of the 
data was obtained from the Ethics Committee of Tottori 
University Faculty of Medicine, Yonago, Japan (approval 
number 20A016). Since this study uses only medical 
data and other information, the details of the study 
were disclosed on the website in advance in accordance 
with the ethical guidelines set by the government. 
Informed consent is waived by ethics committee. 
(Tottori University Faculty of Medicine Ethics Review 
Committee)
Patient selection
Patients with a high PSA level underwent a 1.5- or 
3-Tesla prostate MRI. The PI-RADS was then used to 
rate the lesions. The inclusion criteria were as follows: (1) 
PSA level between 4.0 and 30.0 ng/mL and (2) patients 
with one or more lesions on MRI and a PI-RADS score 
of 3 or more. All enrolled patients were SB naïve or had 
a history of one or more prior negative SBs. None of the 
patients had a history of prior MRF-TB.
Male patients who were under active surveil-
lance (i.e., with a prior positive biopsy) and those who 
underwent MRI prior to the release of the PI-RADS 
were excluded from the analysis. Those who underwent 
prostate procedures, including surgery (e.g., transure-
thral resection of the prostate) or radiation therapy, 
were also excluded. Furthermore, male patients with a 
region of interest of less than PI-RADS score of 3 who 
were administered oral 5α-reductase inhibitors were 
excluded, as well as those who were deemed unsuitable 
by the research manager. Finally, a cohort of 104 men 
was obtained.
For each patient, we recorded the PSA level at 
biopsy, digital rectal examination findings, prostatic 
volume, overall PI-RADS and lesion scores, total num-
ber of biopsy cores obtained, presence of PCa, Gleason 
score (GS), and tumor infiltration. In this study, a GS ≥ 
7 and/or a maximum cancer core length of ≥ 5 mm was 
considered as csPCa.
Magnetic resonance imaging
All male patients underwent a 1.5- or 3-Tesla prostate 
MRI. MRI imaging conditions were in accordance with 
the PI-RADS. Prior to biopsy, all suspicious lesions 
found on prostate MRI were scored by a single board-
certified radiologist with expertise in prostate imaging. 
If mpMRI was initially conducted and read by a third-
party radiologist, a second reading was performed at 
our institution, and scoring was based on the PI-RADS 
guideline recommendations. Additionally, during the 
imaging evaluation, the radiologist was informed about 
patients’ PSA levels, age, and other clinical information.
Prostate biopsy
For all biopsy procedures, the TRINITYTM system 
(Koelis, La Tronche, France) was used under spinal 
epidural anesthesia with the patient in the lithotripsy 
position. First, we visualized three-dimensional (3D) 
volume data obtained from MRI and real-time TRUS 
images. Elastic image fusion was conducted by semi-
automatically contouring the MRI image of the entire 
prostate and suspected lesions on 3D TRUS images. 
A two-core biopsy targeted to each suspicious lesion, 
which was identified on MRI, was followed by a 14-
core SB. If there were three or more MRI lesions, two 
MRF-TBs were performed. In this case, one MRF-TB 
was conducted on the index lesion and another on the 
next suspected lesion. All biopsy cores were obtained 
by a single urologist.
Histological evaluation
The prostate biopsy specimens from each patient were 
assigned to four pathologists with special training, who 
then evaluated their assigned specimens.
Statistical analysis
We traditionally performed a 14-core SB, in which a 
6-core was performed at the basal level (outside, center, 
inside on both sides), a 6-core at the mid-level (outside, 
center, inside on both sides), and a 2-core at the apex 
level (center on both sides) (Fig. 1). In this study, we 
compared how CDRs changed when the number of SBs 
used with MRF-TB was reduced. The CDR in the 10-
core SB, excluding the biopsy results from the center 
of the base and from the mid-level on both sides, was 
evaluated. We used the Mann–Whitney U test for com-
parison between the two groups. Wilcoxon’s signed rank 
test was used to compare the CDR between a 14-core 
SB and a 10-core SB between the two corresponding 
groups. For each test result, a corresponding two-sided 
P value of < 0.05 was considered statistically significant. 
All analyses were performed using the SPSS software 
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version 23.0 (IBM Corporation, Armonk, NY).
RESULTS
Table 1 presents the descriptive statistics of the study 
population. The study included 86 biopsy-naïve patients 
and 18 patients with a prior negative biopsy but with 
persistently high PSA levels. The median patient age 
was 70 years [interquartile range (IQR), 66–74 years]; 
the median PSA level was 8.62 ng/mL (IQR, 6.5–12.6 
ng/mL); and the median prostate volume was 44 mL 
(IQR, 30.7–63.5 mL). All patients underwent simultane-
ous MRF-TB and a 14-core SB. Overall, 60 lesions were 
PI-RADS score of 3, 67 were PI-RADS score of 4, and 
22 were PI-RADS score of 5. In total, 149 lesions were 
subjected to MRF-TB with 2-cores each. There were 
no significant prostate biopsy-related complications 
(Clavien-Dindo grade I) that required hospital admis-
sion in any of the patients.
Patient level
Figure 2 shows the overall CDR and csPCa CDR. The 
combination of SB and TB resulted in the highest CDR. 
Figure 3 shows the prostate CDR of the 14-core and 10-
core SB used in combination. The overall CDR was 
55.8% for the former and 55.8% for the latter, thereby 
indicating that there was no significant difference (P = 
1.00) between the two. In addition, the CDR of csPCa 
was 51.9% for the former and 51.1% for the latter, which 
indicated that there was no significant difference (P = 
0.317) between the two.
Lesion level
In patients with a PI-RADS score of 3, the CDR was 
20.0%, the inflammation rate was 26.7%, and the pros-
tatic intraepithelial neoplasia (PIN) rate was 3.3%. In 
those with a PI–RADS score of 4, the CDR was 56.7%, 
the inflammation rate was 13.4%, and the PIN rate was 
4.5%. In those with a PI-RADS score of 5, the CDR 
was 77.3%, the inflammation rate was 0.0%, and the 
PIN rate was 0.0% (Table 2). The higher the PI-RADS 
score was, the higher the CDR. A PI-RADS score of 4/5 
resulted in a significant difference in CDR compared to 
a PI-RADS score of 3 (Fig. 4). Although patients with 
a PI-RADS score of 3 had a low CDR, this group also 
consisted of patients with a high GS (Fig. 5).
DISCUSSION
In this study, there was no significant difference in the 
CDR between the 14-core and 10-core SBs. Based on 
this result, our facility has reduced the number of biopsy 
cores in SB to 10. In addition, our facility has started 
conducting MRI-TRUS fusion biopsy. Furthermore, 
the combination of SB and MRF–TB resulted in the 
highest CDR in our study. These results were consistent 
with those of the other reports. Likewise, Calio et al. 
found that combining SB with MRF-TB resulted in a 
significantly reduced surgical GS upgrading compared 
with that of SB alone.6 Additionally, patients with a 
PI-RADS score of 3 had a low CDR. Nevertheless, there 
was a certain number of PCa cases with a high GS that 
necessitated proper precaution. Therefore, in patients 
with MRI lesions with a PI-RADS score of 3 or higher, 
we should consider performing MRF-TB.
In recent years, many studies have shown the 
effectiveness of MRF-TB. It was demonstrated that 
the csPCa detection rate of men undergoing MRF-TB 
was higher than that of men undergoing TRUS biopsy.7 
Siddiqui et al. reported that in the prospective single-
group cohort of 1,003 men, the number of high-risk 
cancers detected increased and the number of low-risk 
Fig. 1. Prostate biopsy site. 14-core SB: 6-core at base level (outside, center, inside on both sides), 6-core at mid-level (outside, center, in-
side on both sides), and 2-core at apex level (center on both sides). 10-core SB: 4-core at base level (outside, inside on both sides), 4-core 
at mid-level (outside, inside on both sides), and 2-core at apex level (center on both sides).
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cancers detected decreased with the use of MRF-TB.8 
Baco et al. reported comparable detection rates of csPCa 
between the 2-core MRF-TB and the 12-core SB.9 
Ukimura et al. reported that the TRUS visibility of an 
MR-suspicious lesion facilitates image-guided biopsies, 
resulting in higher detection of csPCa.10 Based on these 
recent studies, MRF-TB has the potential to be a gold 
standard diagnostic tool for men suspected of PCa. In 
addition, MRF-TB has made it possible to determine the 
GS and cancer localization of csPCa with high accuracy, 
making it easier to track the cancer progression of 
individual patients. The detailed information obtained 
by MRF-TB is expected to be applied to the accurate 
adaptation of active surveillance, surgical resection with 
improved curability, and nerve preservation, with fur-
ther application in focal therapy. TRINITYTM records 
the 3D position information of the tissue collected by the 
biopsy and enables 3D display, making it easier to visu-
alize where the cancer tissue is in the prostate. At our 
institution, in cases where robot-assisted laparoscopic 
Table 1. Patients’ characteristics
No. patients 104
Median age, years (IQR) 70 (66–74)
Median ng/mL PSA (IQR) 8.62 (6.5–12.6)
Median ml prostate vol (IQR) 44 (30.7–63.5)
Median mm MRI index lesion diameter (IQR) 10 (7–13)
Prior systematic biopsy (%):
Naive 86 (82.7)
1 Prior negative 15 (14.4)
2 or Greater prior negative 3 (2.9)
Abnormal digital rectal examination (%) 16 (15.4)
No. lesion PI-RADS (%):
 Score 3 60 (40.3)
 Score 4 67 (45.0)




Fig. 2. The overall CDR and the CDR of csPCa. The CDR was compared for the combination of SB and TB, and for TB alone and SB 
alone. We compared the overall CDR and the CDR of csPCa, respectively. The results showed that the combination of SB and TB had the 
highest CDR, but there was no significant difference in CDR between TB and the 14-core SB.
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Fig. 3. The CDR by number of SB. A combination of 14-core SB and TB and 10-core SB and TB were compared with CDR. No 
significant differences were found in the overall CDR and CDR of csPCa.
Table 2. Histopathological results by PI-RADS score
PI-RADS PI-RADS PI-RADS
score of 3 score of 4 score of 5
No. MRI lesion 60 (20.0) 67 (56.7) 22 (77.3)
No. PCa detection (%) 12/60 38/67 17/22
GS = 6 4 7 1
GS = 7 3 23 7
GS ≥ 8 5 8 9
No. inflammation (%) 16/60 (26.7) 9/67 (13.4) 0/22 (0.0)
No. PIN (%) 2/60 (3.3) 3/67 (4.5) 0/22 (0.0)
Fig. 4. The CDR by PI-RADS score. The CDR for PI-RADS score of 3 was 20.0%, the CDR for score of 4 was 56.7%, and the 
CDR for score of 5 was 77.3%. Comparing score 3 and 4/5, the CDR was significantly higher in the latter group (P < 0.001).
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radical prostatectomy is to be performed after MRF-TB, 
it is used to evaluate the localization of cancer in nerve-
preserving surgical selection. Moreover, we tried to 
visually improve the surgical precision by displaying a 
3D model on the da Vinci Surgical SystemTM.
This study compared the change in CDR, as-
suming that the number of SBs used in combination 
with MRF-TB was reduced from 14- to 10 cores in a 
retrospective study. Therefore, it was difficult to as-
sess the substantial risks for complications and costs. 
In general, complications of prostate biopsy include 
hematuria, hematospermia, rectal bleeding, infection, 
pain, and urinary retention. Reducing the number of 
biopsy cores may lead to a reduction in these complica-
tions. However, the effect of the number of biopsy cores 
on hematuria was controversial. Ghani et al. reported 
that in a study involving 760 patients, there was no 
association between the incidence of hematuria and 
the number of biopsy cores (44% for 6 cores, 41% for 
8 cores, and 39% for 12 cores).11 However, there was 
a study that found that an increase in the number of 
biopsy cores led to an increased incidence of hematu-
ria.12 For rectal bleeding, McCormack et al. reported 
an association between the number of biopsy cores and 
anticoagulants.13 In addition, Ghani et al.11 reported that 
the incidence of rectal bleeding was 17% in the 6-core, 
26% in 8-core, and 27% in 10-core SB. These results 
suggested that the incidence of rectal bleeding was 
significantly increased as the number of biopsy cores 
increased.11 Regarding hematospermia, Berger et al. 
reported a significant association between the number 
of biopsy cores (31.8% for 6-cores, 37.4% for 10-cores, 
and 38.4% for 15-cores).14 In addition, some studies 
showed an association between the number of biopsy 
cores and the risk for pain during prostate biopsy.15–17 
The risk for erectile dysfunction after prostate biopsy 
remains unclear. However, it might be related to a com-
bination of psychological factors, such as the stress that 
a PCa diagnosis might confer. Nevertheless, repeated 
biopsies or extensive biopsies of the prostate might lead 
to erectile dysfunction.18 Further, there are no reports 
on the association between the number of biopsy cores 
and the risk for urinary retention. Additionally, a meta-
analysis of infections did not show an association with 
the number of biopsy cores.15, 19, 20
There were a few reports on the cost efficiency of 
fusion biopsy in PCa care. Venderink et al. reported that 
fusion biopsy was superior to SB.21 In the clinical set-
ting, it was important to distinguish csPCa from cisPCa. 
Onik et al. reported that the localization of csPCa can be 
determined via MRI with a 3 mm slice thickness; hence, 
mpMRI is efficient.22 If there is no obvious lesions noted 
on mpMRI, clinical follow-up without prostate biopsy 
can reduce the problem of overdiagnosis and overtreat-
ment.23 mpMRI improves the cost-effectiveness of 
prostate biopsy; however, it should be noted that false 
negatives can occur in approximately 20% of cases.24, 25 
For the above reasons, MRF-TB can efficiently detect 
csPCa and may be cost-effective. However, studies 
on cost-effectiveness, which encompass the cost of 
diagnosis, reduction of overtreatment, and reduction in 
the number of biopsy cores, are limited. These findings 
Fig. 5. GS assessment by PI-RADS score in prostate cancer-positive patients. PI-RADS score of 5 resulted in a high percentage of GS ≥ 8. 
On the other hand, even with PI-RADS score of 3, a certain percentage had GS ≥ 8 findings.
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require further validation. Furthermore, reliably detect-
ing csPCa using MRF-TB only could reduce complica-
tions; however, this is not currently feasible because it 
has been reported that only 17.4% of cribriform tumors 
in pure form were visible on MRI.26 Therefore, with 
the current imaging diagnostic technology, performing 
MRF-TB only on lesions that are detected on MRI 
might result in the underdiagnosis of csPCa. Thus, the 
combination of SB and MRF-TB is considered essential. 
In fact, it has been reported that the false-negative rates 
of csPCa in targeted fusion prostate biopsy were 16.2% 
and 39.7% in patients with a PI-RADS score of 3 or 
greater and those with a PI-RADS score of 4 or greater, 
respectively.27 Although the effectiveness of MRF-TB 
has been reported previously, a study reported that 
there was a learning curve in establishing the MRF-TB 
procedure. Meng et al. reported that the csPCa detection 
rate increased by 26% (50% to 76%, P = 0.025) with 
time in men with a PI-RADS score of 4 or 5 lesion.28 It 
was necessary to perform a certain number of cases to 
master the procedure impeccably. Furthermore, there 
is no clear standard for the number of MRF-TB cores 
to be collected for each MRI lesion. The number of 
TB cores is determined based on the judgment of the 
examiner, whose decision is based on the size and loca-
tion of the lesion noted on MRI. According to Porpiglia 
et al., taking two cores at the center of the index lesion 
regardless of the diameter may provide a more accurate 
CDR and could optimize the chances of finding the 
highest Gleason pattern.29 On the other hand, there were 
skeptical opinions about the use of a 2-core TB. In fact, 
Dimitroulis et al. reported that the diagnostic utility 
did not change there were one or two cores used for the 
target lesion.2, 30
Fusion biopsy results based on pre-biopsy MRI 
findings were effective in many cases. However, the 
significance of SB remains unclear, despite its standard 
utilization since PSA became popular. However, fusion 
biopsy is expensive and time-consuming compared 
with other conventional biopsy techniques. Currently, 
cognitive biopsy, which is less expensive and less time-
consuming, is often the diagnostic tool of choice in 
general clinical practice, except in large hospitals such 
as university hospitals. In the current Japanese medical 
system, fusion biopsy is billed at the same level as that 
of a general cognitive biopsy. This may explain why the 
fusion biopsy is not currently preferred. Nevertheless, 
the future trend may change.
This study confirmed the effectiveness of MRF-TB; 
however, there are some limitations. First, not all pa-
tients undergoing MRF-TB were diagnosed with PCa in 
this study. Furthermore, since not all patients diagnosed 
with PCa selected to undergo curative prostatectomy, 
comparison between the biopsy specimen and the whole 
prostate specimen was incomplete. For these reasons, 
it was not possible to reliably measure the standard 
parameters such as actual sensitivity, specificity, diag-
nostic accuracy, etc. This aspect is considered a major 
limitation of studies focusing on MRF-TB. Second, 
improvements in the PI-RADS and the collaboration 
among radiologists, pathologists, and urologists are 
important factors that have been previously shown 
to contribute to the enhancement of cancer detection 
over time. However, it is difficult to quantify these fac-
tors.31, 32 Third, in this study, the comparison is based 
on the assumption that the number of biopsy cores has 
been reduced. Therefore, we did not compare actual 
biopsy results. Forth, when an examiner is performing 
SB, he/she already has prior knowledge of suspicious le-
sions based on either US images or fusion MR images. 
Therefore, there was a possibility that bias occurred 
during random sampling.
Despite the limitations, our study has several 
strengths. First, at our facility, for all male patients who 
presented with a high PSA value, the possibility of 
selective bias can be reduced to a certain extent because 
we performed MRI prior to biopsy when medically 
possible. Furthermore, since the prostate biopsy was 
performed by a single examiner, we believe that stabil-
ity of the procedure can be achieved.
In conclusion, the 2-core MRF-TB had the same 
CDR as that of the 14-core SB. The combination 
of MRF–TB and SB resulted in the highest CDR. 
However, there was no significant difference in the CDR 
when the number of SB cores to be used in combination 
was 14 and 10. Furthermore, it is still a matter of discus-
sion as to whether these 10 SB cores can be considered 
as optimal biopsy cores. We aim to conduct further 
investigation in the future with a larger the number of 
cases.
The authors declare no conflict of interest.
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